Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- China’s Resilient Economy: First quarter GDP growth data reveals China’s thriving economy despite global challenges.
- Private Investment Surge: China sees a boost in private investment with state capital investors leading tech innovation.
- Startup Funding Soars: Greater China startups secure $20.1 billion in Q1 from PE and VC investors.
- Market Volatility: Investor caution as PE-VC funding for Greater China startups drops 73.4% in April.
- Hong Kong Stock Woes: Hong Kong’s stock market struggles amid investor uncertainty, impacting tech startups.
- VC Concerns: Chinese VCs warn of funding shortages due to IPO freeze affecting tech startups.
- Investor Shift: Chinese VCs and PEs seek funding from Middle Eastern investors with Western backing diminishing.
- Healthcare Sector Deals: Investors move towards hospital acquisitions in Malaysia and Indonesia.
- Funding Highlights: Notable investments include India’s NephroPlus, CarDekho, and Singapore’s Healthium Medtech.
- Financial Updates: Companies like Pharmacity, Atlan, and MAA General Assurance Philippines Inc. announce funding and acquisition deals.
APAC Private Markets Research
Explore latest Insights on APAC Private Markets on Smartkarma
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
Also, check out the latest in ECM Research on Smartkarma
